NASDAQ:OCS Oculis (OCS) Stock Price, News & Analysis → Write this ticker symbol down… (From StocksToTrade) (Ad) Free OCS Stock Alerts $11.85 -0.10 (-0.84%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$11.85▼$12.0050-Day Range$10.81▼$13.0752-Week Range$9.05▼$14.50Volume1,400 shsAverage Volume40,145 shsMarket Capitalization$479.93 millionP/E RatioN/ADividend YieldN/APrice Target$30.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Oculis alerts: Email Address Oculis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside154.6% Upside$30.17 Price TargetShort InterestHealthy0.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.84) to ($2.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.48 out of 5 starsMedical Sector704th out of 903 stocksPharmaceutical Preparations Industry329th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingOculis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOculis has only been the subject of 3 research reports in the past 90 days.Read more about Oculis' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.23% of the float of Oculis has been sold short.Short Interest Ratio / Days to CoverOculis has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oculis has recently increased by 16.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOculis does not currently pay a dividend.Dividend GrowthOculis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCS. Previous Next 3.3 News and Social Media Coverage News SentimentOculis has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Oculis this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Oculis to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oculis insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 22.30% of the stock of Oculis is held by institutions.Read more about Oculis' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Oculis are expected to decrease in the coming year, from ($1.84) to ($2.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oculis is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oculis is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOculis has a P/B Ratio of 4.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Oculis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Oculis Stock (NASDAQ:OCS)Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Read More OCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OCS Stock News HeadlinesJune 4, 2024 | globenewswire.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesJune 3, 2024 | americanbankingnews.comOculis Holding AG (NASDAQ:OCS) Sees Large Growth in Short InterestJune 1, 2024 | americanbankingnews.comBrokerages Set Oculis Holding AG (NASDAQ:OCS) PT at $30.17May 30, 2024 | globenewswire.comOculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory BoardMay 30, 2024 | globenewswire.comOculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory BoardMay 23, 2024 | finance.yahoo.comWhile institutions own 39% of Oculis Holding AG (NASDAQ:OCS), individual investors are its largest shareholders with 55% ownershipMay 18, 2024 | msn.comOCS Stock Earnings: Oculis Holding Misses EPS, Misses Revenue for Q1 2024May 17, 2024 | globenewswire.comOculis updates share capital for its existing at-the-market offering programMay 14, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Oculis Holding (OCS)May 8, 2024 | markets.businessinsider.comOculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic NeuritisMay 8, 2024 | globenewswire.comOculis Reports Q1 2024 Financial Results and Provides Company UpdatesMay 8, 2024 | globenewswire.comOculis Reports Q1 2024 Financial Results and Provides Company UpdatesMay 7, 2024 | globenewswire.comOculis Publishes Invitation to the Annual General MeetingMay 6, 2024 | globenewswire.comOculis to Present at Bank of America Global Healthcare ConferenceApril 29, 2024 | globenewswire.comOculis Publishes Invitation to the Annual General MeetingApril 26, 2024 | investing.comOculis shares target cut, retains buy rating on completed equity financingApril 26, 2024 | markets.businessinsider.comOptimistic Buy Rating for Oculis Holding Ahead of Key OCS-02 Drug Data ReleaseApril 24, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Day One Biopharmaceuticals (DAWN)April 22, 2024 | finanznachrichten.deOculis Holding AG: Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main MarketApril 22, 2024 | globenewswire.comOculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main MarketApril 22, 2024 | globenewswire.comOculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main MarketApril 11, 2024 | globenewswire.comOculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main MarketApril 10, 2024 | globenewswire.comOculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & DevelopmentApril 8, 2024 | globenewswire.comPositive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual MeetingApril 4, 2024 | globenewswire.comOculis to Participate at Upcoming April Investor ConferencesSee More Headlines Receive OCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/10/2024Next Earnings (Estimated)9/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OCS CUSIPN/A CIK1953530 Webwww.oculis.com Phone41-21-711-3970FaxN/AEmployees36Year FoundedN/APrice Target and Rating Average Stock Price Target$30.17 High Stock Price Target$35.00 Low Stock Price Target$24.00 Potential Upside/Downside+154.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-98,920,000.00 Net Margins-6,712.02% Pretax Margin-10,040.34% Return on Equity-52.72% Return on Assets-43.72% Debt Debt-to-Equity Ratio0.01 Current Ratio4.71 Quick Ratio4.71 Sales & Book Value Annual Sales$980,000.00 Price / Sales489.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book4.13Miscellaneous Outstanding Shares40,500,000Free FloatN/AMarket Cap$479.93 million OptionableNot Optionable Beta0.30 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Riad Sherif M.B.A. (Age 56)M.D., CEO & Director Ms. Sylvia Cheung (Age 49)Chief Financial Officer Dr. Ramin Tadayoni M.D.Ph.D., Chief Scientific OfficerMs. Virginia R. Dean (Age 57)Chief Human Resources Officer Dr. Bastian Dehmel M.D. (Age 53)Chief Development Officer Mr. Páll Ragnar Jóhannesson (Age 42)Chief Business Officer Ms. Rebecca WeilChief Commercial OfficerDr. Snehal Shah Pharm.D.President of Research & DevelopmentMore ExecutivesKey CompetitorsArvinasNASDAQ:ARVNCatalyst PharmaceuticalsNASDAQ:CPRXGalapagosNASDAQ:GLPGKeros TherapeuticsNASDAQ:KROSNewAmsterdam PharmaNASDAQ:NAMSView All CompetitorsInstitutional OwnershipNan Fung Group Holdings LtdSold 82,555 shares on 5/14/2024Ownership: 1.077%View All Institutional Transactions OCS Stock Analysis - Frequently Asked Questions Should I buy or sell Oculis stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oculis in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCS shares. View OCS analyst ratings or view top-rated stocks. What is Oculis' stock price target for 2024? 8 Wall Street analysts have issued 12 month target prices for Oculis' shares. Their OCS share price targets range from $24.00 to $35.00. On average, they anticipate the company's share price to reach $30.17 in the next year. This suggests a possible upside of 154.6% from the stock's current price. View analysts price targets for OCS or view top-rated stocks among Wall Street analysts. How have OCS shares performed in 2024? Oculis' stock was trading at $11.23 on January 1st, 2024. Since then, OCS stock has increased by 5.5% and is now trading at $11.85. View the best growth stocks for 2024 here. Are investors shorting Oculis? Oculis saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 46,000 shares, an increase of 16.8% from the April 30th total of 39,400 shares. Based on an average daily trading volume, of 39,100 shares, the short-interest ratio is presently 1.2 days. Approximately 0.2% of the company's stock are short sold. View Oculis' Short Interest. When is Oculis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 3rd 2024. View our OCS earnings forecast. How were Oculis' earnings last quarter? Oculis Holding AG (NASDAQ:OCS) issued its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.03. The business earned $0.22 million during the quarter, compared to analyst estimates of $0.28 million. Oculis had a negative net margin of 6,712.02% and a negative trailing twelve-month return on equity of 52.72%. Who are Oculis' major shareholders? Oculis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Nan Fung Group Holdings Ltd (1.08%). How do I buy shares of Oculis? Shares of OCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:OCS) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I expla...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.